TuHURA Biosciences (NASDAQ:HURA) Upgraded by Wall Street Zen to “Hold” Rating

TuHURA Biosciences (NASDAQ:HURA) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

HURA has been the subject of a number of other reports. Citigroup started coverage on TuHURA Biosciences in a research note on Monday, April 27th. They issued an “outperform” rating for the company. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a research note on Tuesday, February 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Tuesday, April 21st. Rodman & Renshaw started coverage on TuHURA Biosciences in a research note on Wednesday, April 15th. They issued a “buy” rating for the company. Finally, Citizens Jmp started coverage on TuHURA Biosciences in a report on Monday, April 27th. They set a “market outperform” rating and a $9.00 price target on the stock. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

TuHURA Biosciences Price Performance

NASDAQ:HURA opened at $2.50 on Friday. The firm has a 50-day moving average of $2.22 and a two-hundred day moving average of $1.61. The stock has a market cap of $159.20 million, a P/E ratio of -4.10 and a beta of -0.01. TuHURA Biosciences has a 1-year low of $0.41 and a 1-year high of $3.90.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). As a group, equities analysts expect that TuHURA Biosciences will post -0.45 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in TuHURA Biosciences by 1.6% in the third quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock worth $5,629,000 after buying an additional 35,426 shares during the last quarter. Geode Capital Management LLC grew its position in TuHURA Biosciences by 6.4% in the fourth quarter. Geode Capital Management LLC now owns 662,481 shares of the company’s stock worth $501,000 after buying an additional 39,710 shares during the last quarter. State Street Corp grew its position in TuHURA Biosciences by 4.9% during the 4th quarter. State Street Corp now owns 289,133 shares of the company’s stock worth $219,000 after purchasing an additional 13,594 shares in the last quarter. Apollon Wealth Management LLC grew its position in TuHURA Biosciences by 17.7% during the 1st quarter. Apollon Wealth Management LLC now owns 158,010 shares of the company’s stock worth $283,000 after purchasing an additional 23,717 shares in the last quarter. Finally, Cetera Investment Advisers purchased a new position in TuHURA Biosciences during the 1st quarter worth approximately $251,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.